| Bioactivity | hCAI/II-IN-6 is an orally active human carbonic anhydrase (CA) inhibitor. hCAI/II-IN-6 selectively inhibits hCA II and hCA VII isoforms with Ki values of 220, 4.9, 6.5 and ＞50000 nM for hCA I, hCA II , hCA VII and hCA XII respectively. hCAI/II-IN-6 shows anticonvulsant activity and anti maximal electroshock (MES) activity in vivo. hCAI/II-IN-6 can be used for the research of epilepsy[1]. | |||||||||
| Invitro | hCAI/II-IN-6 (0-50 μM) inhibits hCA I, hCA II , hCA VII and hCA XII activities with Ki values of 220, 4.9, 6.5 and ＞50000 nM, respectively[1]. | |||||||||
| In Vivo | hCAI/II-IN-6 (30-100mg/kg; i.p. once) shows good anticonvulsant effect in vivo[1].hCAI/II-IN-6 (30 mg/kg; p.o. once) shows anti-MES activity in vivo[1]. Animal Model: | |||||||||
| Name | hCAI/II-IN-6 | |||||||||
| CAS | 694466-00-7 | |||||||||
| Formula | C19H24N4O3S | |||||||||
| Molar Mass | 388.48 | |||||||||
| Appearance | Solid | |||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | |||||||||
| Storage |
|
|||||||||
| Reference | [1]. Mishra CB, et al. Discovery of Benzenesulfonamides with Potent Human Carbonic Anhydrase Inhibitory and Effective Anticonvulsant Action: Design, Synthesis, and Pharmacological Assessment. J Med Chem. 2017 Mar 23;60(6):2456-2469. |
hCAI/II-IN-6
CAS: 694466-00-7 F: C19H24N4O3S W: 388.48
hCAI/II-IN-6 is an orally active human carbonic anhydrase (CA) inhibitor. hCAI/II-IN-6 selectively inhibits hCA II and h
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.